These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18559720)

  • 1. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure.
    Pitt B; Ahmed A; Love TE; Krum H; Nicolau J; Cardoso JS; Parkhomenko A; Aschermann M; Corbalán R; Solomon H; Shi H; Zannad F
    Hypertension; 2008 Aug; 52(2):271-8. PubMed ID: 18559720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction.
    Ahmed A; Pitt B
    Am J Cardiol; 2009 May; 103(10):1374-80. PubMed ID: 19427431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
    Pitt B; White H; Nicolau J; Martinez F; Gheorghiade M; Aschermann M; van Veldhuisen DJ; Zannad F; Krum H; Mukherjee R; Vincent J;
    J Am Coll Cardiol; 2005 Aug; 46(3):425-31. PubMed ID: 16053953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.
    Montalescot G; Pitt B; Lopez de Sa E; Hamm CW; Flather M; Verheugt F; Shi H; Turgonyi E; Orri M; Vincent J; Zannad F; ;
    Eur Heart J; 2014 Sep; 35(34):2295-302. PubMed ID: 24780614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
    Adamopoulos C; Ahmed A; Fay R; Angioi M; Filippatos G; Vincent J; Pitt B; Zannad F;
    Eur J Heart Fail; 2009 Nov; 11(11):1099-105. PubMed ID: 19875410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
    Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
    Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
    Carillo S; Zhang Y; Fay R; Angioi M; Vincent J; Sutradhor SC; Ahmed A; Pitt B; Zannad F
    Arch Cardiovasc Dis; 2014 Mar; 107(3):149-57. PubMed ID: 24630753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of selective aldosterone antagonists.
    Weinberger MH
    Curr Hypertens Rep; 2004 Oct; 6(5):342-5. PubMed ID: 15341684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
    Rossignol P; Cleland JG; Bhandari S; Tala S; Gustafsson F; Fay R; Lamiral Z; Dobre D; Pitt B; Zannad F
    Circulation; 2012 Jan; 125(2):271-9. PubMed ID: 22128223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone in patients with acute myocardial infarction complicated by heart failure.
    Ramaraj R
    Hypertension; 2008 Dec; 52(6):e147; author reply e48. PubMed ID: 18936342
    [No Abstract]   [Full Text] [Related]  

  • 14. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
    [No Abstract]   [Full Text] [Related]  

  • 15. Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) substudy.
    Regnault V; Lagrange J; Pizard A; Safar ME; Fay R; Pitt B; Challande P; Rossignol P; Zannad F; Lacolley P
    Hypertension; 2014 Jan; 63(1):105-11. PubMed ID: 24126172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure.
    Deedwania PC; Ahmed MI; Feller MA; Aban IB; Love TE; Pitt B; Ahmed A
    Eur J Heart Fail; 2011 May; 13(5):551-9. PubMed ID: 21393298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eplerenone in patients with systolic heart failure and mild symptoms.
    Zannad F; McMurray JJ; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B;
    N Engl J Med; 2011 Jan; 364(1):11-21. PubMed ID: 21073363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.